Glioblastoma study discovers protective role of metabolic enzyme, revealing a novel therapeutic target
Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel function for the metabolic enzyme medium-chain acyl-CoA dehydrogenase (MCAD) in glioblastoma (GBM). MCAD prevents toxic lipid buildup, in addition to its normal role in energy production, so targeting MCAD causes irreversible damage and cell death specifically in cancer cells.
The study was published today in Cancer Discovery, a journal of...
New AI-based tool can find rare cell populations in large single-cell datasets
Researchers at The University of Texas MD Anderson Cancer Center have developed a first-of-its-kind artificial intelligence (AI)-based tool...
Metabolic inhibitor IACS-6274 shows early antitumor effects in underserved patients with advanced cancers
ABSTRACT #3001
The glutaminase (GLS1) inhibitor IACS-6274, discovered and developed by The University of Texas MD Anderson Cancer Center...
MD Anderson and Refuge Biotechnologies collaborate to advance next-generation cell therapies for treatment of solid tumors
The University of Texas MD Anderson Cancer Center and Refuge Biotechnologies, Inc. today announced a strategic collaboration to advance new cell therapies for potential treatment of solid tumors. The agreement pairs Refuge’s innovative technologies with the experience and industrial capabilities of MD Anderson’s Biologics Development platform, within the Therapeutics Discovery division.
Under the agreement, MD Anderson will...
NK cells with bispecific antibody show activity against lymphoma cells
Cytokine-activated natural killer (NK) cells derived from donated umbilical cord blood, combined with an investigational bispecific antibody...
Mitochondrial enzyme found to block cell death pathway points to new cancer treatment strategy
The mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) plays an important and previously unknown role in blocking a form of cell death...
MD Anderson and Broad Institute launch new translational research platform focused on rare cancers
The University of Texas MD Anderson Cancer Center and the Broad Institute of MIT and Harvard today announced the launch of a new translational...
Single-cell map of early stage lung cancer and normal lung sheds light on tumor development, new therapeutic targets
Researchers at The University of Texas MD Anderson Cancer Center have developed a first-of-its-kind spatial atlas of early-stage lung cancer...